Page 126 - 《中国药房》2025年2期

[22] CHEN Y，CHEN Z J，CHEN R，et al. Immunotherapy- [J]. Front Oncol，2021，11：671228.
based combination strategies for treatment of EGFR-TKI- [32] WANG P L，FANG X Z，YIN T W，et al. Efficacy and
resistant non-small-cell lung cancer[J]. Future Oncol， safety of anti-PD-1 plus anlotinib in patients with ad‐
2022，18（14）：1757-1775. vanced non-small-cell lung cancer after previous systemic
[23] GETTINGER S，HELLMANN M D，CHOW L Q M，et treatment failure：a retrospective study[J]. Front Oncol，
al. Nivolumab plus erlotinib in patients with EGFR- 2021，11：628124.
mutant advanced NSCLC[J]. J Thorac Oncol，2018，13 [33] LU S，WU L，JIAN H，et al. Sintilimab plus bevacizumab
（9）：1363-1372. biosimilar IBI305 and chemotherapy for patients with
[24] OXNARD G R，YANG J C，YU H，et al. TATTON：a EGFR-mutated non-squamous non-small-cell lung cancer
multi-arm，phase Ⅰb trial of osimertinib combined with who progressed on EGFR tyrosine-kinase inhibitor therapy
selumetinib，savolitinib，or durvalumab in EGFR-mutant （ORIENT-31）：first interim results from a randomised，
lung cancer[J]. Ann Oncol，2020，31（4）：507-516. double-blind，multicentre，phase Ⅲ trial[J]. Lancet Oncol，
[25] RIUDAVETS M，NAIGEON M，TEXIER M，et al. Gefi‐ 2022，23（9）：1167-1179.
tinib plus tremelimumab combination in refractory non- [34] PARK S，KIM T M，HAN J Y，et al. Phase Ⅲ ，rando-
small cell lung cancer patients harbouring EGFR muta‐ mized study of atezolizumab plus bevacizumab and chemo-
tions：the GEFTREM phase Ⅰ trial[J]. Lung Cancer， therapy in patients with EGFR- or ALK-mutated non-
2022，166：255-264. small-cell lung cancer（ATTLAS，KCSG-LU19-04）[J]. J
[26] JIANG T，WANG P Y，ZHANG J，et al. Toripalimab plus Clin Oncol，2024，42（11）：1241-1251.
chemotherapy as second-line treatment in previously [35] QIN B D，JIAO X D，YUAN L Y，et al. Immunotherapy-
EGFR-TKI treated patients with EGFR-mutant-advanced based regimens for patients with EGFR-mutated non-
NSCLC：a multicenter phase-Ⅱ trial[J]. Signal Transduct small cell lung cancer who progressed on EGFR-TKI
Target Ther，2021，6（1）：355. therapy[J]. J Immunother Cancer，2024，12（4）：e008818.
[27] ZHANG J，ZHOU C，ZHAO Y，et al. MA11.06 A PⅡ [36] MAREI H E，HASAN A，POZZOLI G，et al. Cancer im‐
study of toripalimab，a PD-1 mAb，in combination with munotherapy with immune checkpoint inhibitors（ICIs）：
chemotherapy in EGFR advanced NSCLC patients failed potential，mechanisms of resistance，and strategies for re‐
+
to prior EGFR-TKI therapies[J]. J Thorac Oncol，2019，14 invigorating T cell responsiveness when resistance is
（Suppl. 10）：S292. acquired[J]. Cancer Cell Int，2023，23（1）：64.
[28] MOK T，NAKAGAWA K，PARK K，et al. Nivolumab [37] SHI A P，TANG X Y，XIONG Y L，et al. Immune check‐
plus chemotherapy in epidermal growth factor receptor- point LAG3 and its ligand FGL1 in cancer[J]. Front Im‐
mutated metastatic non-small-cell lung cancer after di- munol，2021，12：785091.
sease progression on epidermal growth factor receptor [38] WANG J，SANMAMED M F，DATAR I，et al. Fibrinogen-
tyrosine kinase inhibitors：final results of CHECKMATE like protein 1 is a major immune inhibitory ligand of
722[J]. J Clin Oncol，2024，42（11）：1252-1264. LAG-3[J]. Cell，2019，176（1/2）：334-347.e12.
[29] YANG J C，LEE D H，LEE J S，et al. Phase Ⅲ [39] CAI L T，LI Y C，TAN J X，et al. Targeting LAG-3，TIM-
KEYNOTE-789 study of pemetrexed and platinum with 3，and TIGIT for cancer immunotherapy[J]. J Hematol On‐
or without pembrolizumab for tyrosine kinase inhibitor- col，2023，16（1）：101.
resistant，EGFR-mutant，metastatic nonsquamous non- [40] CHEN X Y，LI Y D，XIE Y H，et al. Nivolumab and
small cell lung cancer[J]. J Clin Oncol，2024，42（34）： relatlimab for the treatment of melanoma[J]. Drugs Today，
4029-4039. 2023，59（2）：91-104.
[30] XIONG Q，QIN B Y，XIN L L，et al. Real-world efficacy [41] BURUGU S，GAO D，LEUNG S，et al. LAG-3 tumor in‐
+
and safety of anlotinib with and without immunotherapy filtrating lymphocytes in breast cancer：clinical correlates
in advanced non-small cell lung cancer[J]. Front Oncol， and association with PD-1/PD-L1 tumors[J]. Ann Oncol，
+
2021，11：659380. 2017，28（12）：2977-2984.
[31] CHEN Y，YANG Z Y，WANG Y N，et al. Pembrolizumab （收稿日期：2024-06-24 修回日期：2024-12-24）
plus chemotherapy or anlotinib vs. pembrolizumab alone （编辑：邹丽娟）
in patients with previously treated EGFR-mutant NSCLC

· 244 · China Pharmacy 2025 Vol. 36 No. 2 中国药房 2025年第36卷第2期